Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists

被引：0
|
作者：
Nguyen, Jennifer
Patel, Jeetvan
Kang, Barinder
Yu, Channing
Sawhney, Amrita
Fallick, Mark
Gorritz, Magdaliz
Chen, Chi-Chang
Paltanwale, Queenie
Sun, Kainan
Shore, Neal D.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] IQVIA Inc, Wayne, PA USA
[3] GenesisCare, Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17048
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Successful handling of an accidental extravasation of 177Lu-PSMA-617 in the treatment of advanced prostate cancer
    Jueptner, Michael
    Zuhayra, Maaz
    Assam, Isong
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (02): : N10 - N12
  • [22] Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Lee, Vivian
    O'Brien, Sophia
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) : 301 - 304
  • [23] Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)
    Bergstrom, Colin P.
    Song, Hong
    Ruiz, Shann Mika
    Chien, Joanne
    Moore, Kaidi
    Parikh, Divya Ahuja
    Shah, Sumit
    Fan, Alice C.
    Srinivas, Sandy
    Iagaru, Andrei
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 86 - 86
  • [24] Feasibility of 177Lu-PSMA-617 radioligand therapy in a patient with recurrent high-grade glioma
    Holzgreve, A.
    Delker, A.
    Wenter, V.
    Zacherl, M. J.
    Thon, N.
    Harter, P.
    Brendel, M.
    Unterrainer, L. M.
    Niyazi, M.
    Bartenstein, P.
    von Baumgarten, L.
    Albert, N. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S217 - S217
  • [25] Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy
    Chakraborty, Avik
    Mitra, Arpit
    Tawate, Megha
    Sahoo, Sudip
    Lad, Sangita
    Rakshit, Sutapa
    Gaikwad, Sujay
    Basu, Sandip
    Shimpi, Hemant
    Banerjee, Sharmila
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021, 36 (08) : 682 - 692
  • [26] Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient
    Usmani, Sharjeel
    Al Kandari, Fareeda
    Alrekhais, Ibrahim
    N. Khalaf, Shatha
    Ahmed, Najeeb
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (02) : E213 - E214
  • [27] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [28] The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177Lu-PSMA-617 in the Treatment Paradigm for mCRPC
    Rahbar, Kambiz
    Boegemann, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (02) : 224 - 225
  • [29] Efficacy and Safety of 177Lu-PSMA-617 Treatment in Castration Resistant Prostate Cancer with Organ Metastasis
    Sahin, O. E.
    Akgun, E.
    Demirci, E.
    Ocak, M.
    Akgun, A.
    Akovali, B.
    Karayel, E.
    Pehlivanoglu, H.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S237 - S237
  • [30] Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
    Nauseef, Jones Trevor
    Thomas, Charlene
    Sun, Michael
    Jacobs, Nicole
    Fajardo, Andres Ricaurte
    Ruder, Sam
    Fernandez, Escarleth
    Davidson, Zachary
    Patel, Amie
    Sartor, A. Oliver
    Vallabhajosula, Shankar
    Molina, Ana
    Sternberg, Cora N.
    Nanus, David M.
    Castellanos, Sandra Huicochea
    Osborne, Joseph
    Bander, Neil H.
    Perk, Timothy
    Tagawa, Scott
    CANCER RESEARCH, 2024, 84 (07)
12345